Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin

被引:9
作者
Watanabe, Daichi [1 ]
Fujii, Hironori [1 ]
Yamada, Yunami [1 ]
Iihara, Hirotoshi [1 ]
Ishihara, Takuma [2 ]
Matsuhashi, Nobuhisa [3 ]
Takahashi, Takao [3 ]
Yoshida, Kazuhiro [3 ]
Suzuki, Akio [1 ]
机构
[1] Gifu Univ Hosp, Dept Pharm, Yanagido 1-1, Gifu 5011194, Japan
[2] Gifu Univ, Gifu Univ Hosp, Innovat & Clin Res Promot Ctr, Gifu, Japan
[3] Gifu Univ, Dept Surg Oncol, Grad Sch Med, Gifu, Japan
关键词
Oxaliplatin; creatinine clearance; adverse events; colorectal cancer; nausea; CAPECITABINE PLUS OXALIPLATIN; III COLON-CANCER; PHASE-III; 1ST-LINE TREATMENT; ADJUVANT TREATMENT; FLUOROURACIL; LEUCOVORIN; PHARMACOKINETICS; THERAPY; CHEMOTHERAPY;
D O I
10.21873/anticanres.13953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: To clarify whether renal dysfunction affects the incidence of adverse events associated with oxaliplatin, the present study was designed to investigate the relationship between creatinine clearance (Ccr) and the incidence of oxaliplatin-related adverse events. Patients and Methods: A total of 287 CRC patients who received the first cycle of oxaliplatin-based chemotherapy were eligible. Adverse events, including nausea, vomiting, neutropenia and thrombocytopenia, were graded, and the relationship between Ccr and the incidence of adverse events was examined using multivariable logistic regression analysis. Results: A multivariable analysis indicated that the incidence of grade >= 2 nausea increased, while the incidence of other adverse events tended to be higher, as the Ccr decreased. Particularly, renal dysfunction (Ccr <60 ml/min) was a significant risk factor for grade >= 2 nausea (p=0.042). Conclusion: Care should be taken to avoid adverse events associated with oxaliplatin in patients with renal dysfunction.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [41] Relationship between the Renal Function and Adverse Clinical Events in Patients with Atrial Fibrillation: A Japanese Multicenter Registry Substudy
    Yuzawa, Yasuhumi
    Kuronuma, Keiichiro
    Okumura, Yasuo
    Yokoyama, Katsuaki
    Matsumoto, Naoya
    Tachibana, Eizo
    Oiwa, Koji
    Matsumoto, Michiaki
    Kojima, Toshiaki
    Haruta, Hironori
    Nomoto, Kazumiki
    Sonoda, Kazumasa
    Arima, Ken
    Kogawa, Rikitake
    Takahashi, Fumiyuki
    Kotani, Tomobumi
    Okubo, Kimie
    Fukushima, Seiji
    Itou, Satoru
    Kondo, Kunio
    Chiku, Masaaki
    Ohno, Yasumi
    Onikura, Motoyuki
    Hirayama, Atsushi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
  • [42] Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study
    Palapinyo, Sirinoot
    Klaewsongkram, Jettanong
    Sriuranpong, Virote
    Areepium, Nutthada
    PHARMACY PRACTICE-GRANADA, 2022, 20 (02):
  • [43] Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
    Ge, Pu
    Han, Chunyan
    Reyila, Abudurousuli
    Liu, Diyue
    Hong, Wenying
    Liu, Jiaxin
    Zhang, Jinzi
    Han, Xiao
    Li, Xialei
    Huang, Mengjie
    Fan, Siyuan
    Kaierdebieke, Ayidana
    Wu, Xiaoyu
    Huang, Xiaolu
    Guo, Weirui
    Liu, Siyu
    Bian, Ying
    MEDICINE, 2023, 102 (35) : E34793
  • [44] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
    Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical Oncology
    Chinese Journal of Clinical Oncology, 2007, (06) : 397 - 400
  • [45] Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale
    Kaiser, Karen
    Lyleroehr, Madison
    Shaunfield, Sara
    Lacson, Leilani
    Corona, Maria
    Kircher, Sheetal
    Nittve, Malin
    Cella, David
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (02) : 205 - 218
  • [46] Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI
    Catalano, Martina
    Lavacchi, Daniele
    Giommoni, Elisa
    Shabani, Sonia
    Guidolin, Alessia
    Brugia, Marco
    Petrioli, Roberto
    Ramello, Monica
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    Roviello, Giandomenico
    FUTURE ONCOLOGY, 2023, 19 (38) : 2537 - 2546
  • [47] Preventing adverse events of chemotherapy for gastrointestinal cancer by educating patients about the nocebo effect: a randomized-controlled trial
    Michnevich, T.
    Pan, Y.
    Hendi, A.
    Oechsle, K.
    Stein, A.
    Nestoriuc, Y.
    BMC CANCER, 2022, 22 (01)
  • [48] Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients
    Velasco, Roser
    Bruna, Jordi
    Briani, Chiara
    Argyriou, Andreas A.
    Cavaletti, Guido
    Alberti, Paola
    Frigeni, Barbara
    Cacciavillani, Mario
    Lonardi, Sara
    Cortinovis, Diego
    Cazzaniga, Marina
    Santos, Cristina
    Kalofonos, Haralabos P.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (04) : 392 - 398
  • [49] Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
    Ohhara, Yoshihito
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    ONCOTARGETS AND THERAPY, 2015, 8 : 529 - 537
  • [50] Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis
    Wen, F.
    Zhou, Y.
    Wang, W.
    Hu, Q. C.
    Liu, Y. T.
    Zhang, P. F.
    Du, Z. D.
    Dai, J.
    Li, Q.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 171 - 178